(16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene
| Title | Journal |
|---|---|
| Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. | Molecular diagnosis & therapy 20121001 |
| JAK2 inhibitors and their impact in myeloproliferative neoplasms. | Hematology (Amsterdam, Netherlands) 20120401 |
| Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis. | Journal of medicinal chemistry 20120322 |
| Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor. | Acta pharmacologica Sinica 20120201 |
| SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. | Leukemia 20111101 |
| Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. | Journal of medicinal chemistry 20110714 |